CD274 and non-small cell lung carcinoma: An international retrospective study found an increased objective response rate (ORR, OR 1.61, 95% CI 1.04–2.50) as well as longer PFS (HR 0.61, 95% CI 0.45–0.82) and OS (HR 0.70, 95% CI 0.49–0.99, Table 1) in baseline obese patients with metastatic NSCLC compared to normal BMI patients who had PD-L1 expression ≥50% and were treated with first-line pembrolizumab (n = 962) [33].